EP3077399A4 - Procédés utiles pour la synthèse d'analogues d'halichondrine b - Google Patents

Procédés utiles pour la synthèse d'analogues d'halichondrine b Download PDF

Info

Publication number: EP3077399A4
Authority: EP; European Patent Office
Prior art keywords: halichondrin; analogs; synthesis; methods useful; useful
Prior art date: 2013-12-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14866945.0A

Other languages

German (de)

English (en)

Other versions

EP3077399A1 (fr

EP3077399B1 (fr

Inventor

Bryan M. Lewis

Yongbo Hu

Huiming Zhang

Hiroyuki Chiba

Yuki Komatsu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai R&D Management Co Ltd

Original Assignee

Eisai R&D Management Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-06

Filing date

2014-12-05

Publication date

2017-05-10

2014-12-05 Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd

2014-12-05 Priority to EP18209462.3A priority Critical patent/EP3505520A1/fr

2016-10-12 Publication of EP3077399A1 publication Critical patent/EP3077399A1/fr

2017-05-10 Publication of EP3077399A4 publication Critical patent/EP3077399A4/fr

2019-02-20 Application granted granted Critical

2019-02-20 Publication of EP3077399B1 publication Critical patent/EP3077399B1/fr

Status Active legal-status Critical Current

2034-12-05 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EP14866945.0A 2013-12-06 2014-12-05 Procédés utiles pour la synthèse d'analogues d'halichondrine b Active EP3077399B1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP18209462.3A EP3505520A1 (fr)	2013-12-06	2014-12-05	Procédés utiles dans la synthèse d'analogues d'halichondrine b

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361912714P	2013-12-06	2013-12-06
PCT/US2014/068834 WO2015085193A1 (fr)	2013-12-06	2014-12-05	Procédés utiles pour la synthèse d'analogues d'halichondrine b

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP18209462.3A Division-Into EP3505520A1 (fr)	2013-12-06	2014-12-05	Procédés utiles dans la synthèse d'analogues d'halichondrine b
EP18209462.3A Division EP3505520A1 (fr)	2013-12-06	2014-12-05	Procédés utiles dans la synthèse d'analogues d'halichondrine b

Publications (3)

Publication Number	Publication Date
EP3077399A1 EP3077399A1 (fr)	2016-10-12
EP3077399A4 true EP3077399A4 (fr)	2017-05-10
EP3077399B1 EP3077399B1 (fr)	2019-02-20

Family

ID=53270478

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP18209462.3A Pending EP3505520A1 (fr)	2013-12-06	2014-12-05	Procédés utiles dans la synthèse d'analogues d'halichondrine b
EP14866945.0A Active EP3077399B1 (fr)	2013-12-06	2014-12-05	Procédés utiles pour la synthèse d'analogues d'halichondrine b

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP18209462.3A Pending EP3505520A1 (fr)	2013-12-06	2014-12-05	Procédés utiles dans la synthèse d'analogues d'halichondrine b

Country Status (13)

Country	Link
US (4)	US9303039B2 (fr)
EP (2)	EP3505520A1 (fr)
JP (3)	JP6443812B2 (fr)
CN (1)	CN105916861B (fr)
BR (1)	BR112016012237B1 (fr)
CA (1)	CA2931788C (fr)
ES (1)	ES2723355T3 (fr)
HU (1)	HUE043088T2 (fr)
IL (4)	IL245661A0 (fr)
MX (3)	MX376869B (fr)
RU (1)	RU2676486C1 (fr)
SG (2)	SG10201805024YA (fr)
WO (1)	WO2015085193A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2522663B1 (fr)	2004-06-03	2015-04-01	Eisai R&D Management Co., Ltd.	Intermédiaires pour la préparation d'halichondrine b
RU2489437C2 (ru)	2007-10-03	2013-08-10	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Промежуточные соединения и способы синтеза аналогов галихондрина в
US8598373B2 (en)	2008-04-04	2013-12-03	Eisai R&D Management Co., Ltd.	Halichondrin B analogs
JP5800834B2 (ja)	2010-01-26	2015-10-28	エーザイ・アール・アンド・ディー・マネジメント株式会社	ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体
CN114716453A (zh)	2013-11-04	2022-07-08	卫材R&D管理有限公司	软海绵素b的类似物合成中有用的大环化反应和中间体
JP6443812B2 (ja) *	2013-12-06	2018-12-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	ハリコンドリンｂ類縁体の合成に有用な方法
JP2017520586A (ja)	2014-06-30	2017-07-27	プレジデントアンドフェローズオブハーバードカレッジ	ハリコンドリン類似体の合成およびその使用
WO2016176560A1 (fr)	2015-04-30	2016-11-03	President And Fellows Of Harvard College	Couplage induit par chrome et application à la synthèse d'halichondrines
WO2016179607A1 (fr)	2015-05-07	2016-11-10	Eisai R&D Management Co., Ltd.	Réactions de macrocyclisation et intermédiaires et autres fragments utiles dans la synthèse de macrolides halichondrine
MX377663B (es)	2016-02-12	2025-03-11	Eisai R&D Man Co Ltd	Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
EP3423105B1 (fr)	2016-03-02	2021-05-05	Eisai R&D Management Co., Ltd.	Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MX390072B (es)	2016-06-30	2025-03-20	Eisai R&D Man Co Ltd	Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
JP6978758B2 (ja)	2016-11-11	2021-12-08	プレジデントアンドフェローズオブハーバードカレッジ	パラジウム媒介ケトール化
HUE060466T2 (hu)	2017-04-05	2023-03-28	Harvard College	Makrociklusos vegyület és alkalmazása
US9938288B1 (en)	2017-04-05	2018-04-10	President And Fellows Of Harvard College	Macrocyclic compound and uses thereof
WO2018217894A1 (fr) *	2017-05-24	2018-11-29	Eisai R&D Management Co., Ltd.	Dérivés d'halichondrine marqués au fluor et procédés de synthèse associés
US11498892B2 (en)	2017-07-06	2022-11-15	President And Fellows Of Harvard College	Fe/Cu-mediated ketone synthesis
BR112020000141A2 (pt)	2017-07-06	2020-07-14	President And Fellows Of Harvard College	síntese de halicondrinas
CN109694379B (zh) *	2017-10-24	2020-09-11	江苏恒瑞医药股份有限公司	用于制备艾日布林的中间体及其制备方法
ES2974243T3 (es)	2017-11-15	2024-06-26	Harvard College	Compuestos macrocíclicos y usos de los mismos
WO2019097073A1 (fr)	2017-11-20	2019-05-23	Basilea Pharmaceutica International AG	Associations pharmaceutiques destinées à être utilisées dans le traitement du cancer
CN111868044B (zh)	2018-01-03	2024-07-19	卫材R&D管理有限公司	可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物
CN112437775A (zh) *	2018-07-20	2021-03-02	雷迪博士实验室有限公司	用于制备艾日布林及其中间体的纯化方法
CN113166096A (zh) *	2018-10-09	2021-07-23	雷迪博士实验室有限公司	制备艾立布林的方法及其中间体
US20220089607A1 (en) *	2018-11-28	2022-03-24	Natco Pharma Limited	Process for the preparation of high pure eribulin and its mesylate salt
US11447499B2 (en)	2019-06-14	2022-09-20	Rk Pharma Inc.	Process for the preparation of eribulin mesylate intermediate
WO2022101931A1 (fr) *	2020-11-10	2022-05-19	Natco Pharma Limited	Procédé de préparation d'éribuline et de ses intermédiaires
CN113354659B (zh) *	2021-06-08	2022-04-08	江苏慧聚药业股份有限公司	甲磺酸艾日布林的合成
CN114380840B (zh) *	2022-01-27	2024-01-26	江苏慧聚药业股份有限公司	艾日布林的合成
WO2025106586A1 (fr) *	2023-11-13	2025-05-22	Luxvitae Therapeutics Inc.	Composés cétoniques macrocycliques et leurs applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070244187A1 (en) *	2004-06-03	2007-10-18	Eisai Co., Ltd	Intermediates for the Preparation of Halichondrin B

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU652180A1 (ru)	1975-12-16	1979-03-15	Краснодарский политехнический институт	1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5436238A (en)	1992-03-12	1995-07-25	President And Fellows Of Harvard College	Halichondrins and related compounds
US5338865A (en)	1992-03-12	1994-08-16	President And Fellows Of Harvard College	Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en)	1992-03-23	1992-05-06	Pharma Mar Sa	Cytotoxic compound from a marine sponge
TW255880B (fr)	1992-09-09	1995-09-01	Hoechst Ag
US6194586B1 (en) *	1996-09-06	2001-02-27	Eli Lilly And Company	Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
CN1216051C (zh)	1998-06-17	2005-08-24	卫材株式会社	大环类似物及其使用和制备的方法
US6653341B1 (en)	1998-06-17	2003-11-25	Eisai Co., Ltd.	Methods and compositions for use in treating cancer
US8097648B2 (en)	1998-06-17	2012-01-17	Eisai R&D Management Co., Ltd.	Methods and compositions for use in treating cancer
CN109180615A (zh) *	2004-06-03	2019-01-11	卫材R&D管理有限公司	用于制备软海绵素b的类似物的中间体
US20060045846A1 (en)	2004-08-30	2006-03-02	Horstmann Thomas E	Reagents and methods for labeling terminal olefins
EP1831697A4 (fr)	2004-12-09	2011-01-26	Eisai R&D Man Co Ltd	Criblage de l'isotype tubuline en therapie du cancer faisant appel aux analogues de l'halichondrine b
WO2008010776A1 (fr)	2006-07-21	2008-01-24	Agency For Science, Technology And Research	Aigialomycine d et ses dérivés et leur utilisation dans le traitement de cancer ou de paludisme ou d'infection microbienne
JPWO2009014105A1 (ja)	2007-07-20	2010-10-07	株式会社山田養蜂場本社	新規カルボン酸およびそれを有効成分とする抗うつ用組成物
RU2489437C2 (ru)	2007-10-03	2013-08-10	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Промежуточные соединения и способы синтеза аналогов галихондрина в
CA2705383A1 (fr)	2007-11-16	2009-05-22	Eisai R&D Management Co., Ltd.	Nouveau produit intermediaire pour la synthese de l'analogue de l'halichondrine b et nouvelle reaction de desulfonylation utilisee pour le produit intermediaire
US8598373B2 (en) *	2008-04-04	2013-12-03	Eisai R&D Management Co., Ltd.	Halichondrin B analogs
JP5371091B2 (ja)	2009-01-23	2013-12-18	三菱レイヨン株式会社	モノスルホン酸エステルの製造方法
JP5800834B2 (ja)	2010-01-26	2015-10-28	エーザイ・アール・アンド・ディー・マネジメント株式会社	ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体
EP2354128A1 (fr)	2010-02-10	2011-08-10	Sandoz Ag	Procédé pour la préparation de rivaroxaban
WO2012147900A1 (fr)	2011-04-28	2012-11-01	Eisai R&D Management Co., Ltd.	Procédé en microréacteurs pour synthèse d'analogue d'halichondrine b
EP2785687B1 (fr)	2011-11-30	2019-02-20	Sandoz AG	Procédé de préparation de (3r)-2,4-di-groupe partant-3-méthylbut-1-ène
EP2831082B1 (fr)	2012-03-30	2019-02-20	Sandoz AG	Procédé de synthèse pour la préparation d'analogues c1-céto macrocycliques de l'halichondrine b et intermédiaires utiles dans celui-ci
CA2916537C (fr)	2013-07-03	2021-07-27	Alphora Research Inc.	Procede de synthese pour la preparation d'analogues c1-ceto macrocycliques de l'halichondrine b et intermediaires utiles dans la synthese, notamment des intermediaires contenant d es groupes -so2-(p-tolyle)
CN114716453A (zh)	2013-11-04	2022-07-08	卫材R&D管理有限公司	软海绵素b的类似物合成中有用的大环化反应和中间体
JP6443812B2 (ja) *	2013-12-06	2018-12-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	ハリコンドリンｂ類縁体の合成に有用な方法
WO2016179607A1 (fr)	2015-05-07	2016-11-10	Eisai R&D Management Co., Ltd.	Réactions de macrocyclisation et intermédiaires et autres fragments utiles dans la synthèse de macrolides halichondrine
MX377663B (es)	2016-02-12	2025-03-11	Eisai R&D Man Co Ltd	Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
MX390072B (es)	2016-06-30	2025-03-20	Eisai R&D Man Co Ltd	Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.

2014
- 2014-12-05 JP JP2016532033A patent/JP6443812B2/ja active Active
- 2014-12-05 MX MX2019011926A patent/MX376869B/es active IP Right Grant
- 2014-12-05 HU HUE14866945A patent/HUE043088T2/hu unknown
- 2014-12-05 WO PCT/US2014/068834 patent/WO2015085193A1/fr not_active Ceased
- 2014-12-05 MX MX2020004855A patent/MX384292B/es unknown
- 2014-12-05 BR BR112016012237-2A patent/BR112016012237B1/pt active IP Right Grant
- 2014-12-05 MX MX2016006891A patent/MX370611B/es active IP Right Grant
- 2014-12-05 CA CA2931788A patent/CA2931788C/fr active Active
- 2014-12-05 EP EP18209462.3A patent/EP3505520A1/fr active Pending
- 2014-12-05 ES ES14866945T patent/ES2723355T3/es active Active
- 2014-12-05 SG SG10201805024YA patent/SG10201805024YA/en unknown
- 2014-12-05 US US14/562,086 patent/US9303039B2/en active Active
- 2014-12-05 RU RU2016124265A patent/RU2676486C1/ru active
- 2014-12-05 SG SG11201604545XA patent/SG11201604545XA/en unknown
- 2014-12-05 CN CN201480066353.XA patent/CN105916861B/zh active Active
- 2014-12-05 EP EP14866945.0A patent/EP3077399B1/fr active Active
2016
- 2016-03-03 US US15/059,965 patent/US9695188B2/en active Active
- 2016-05-16 IL IL245661A patent/IL245661A0/en active IP Right Grant
2017
- 2017-06-30 US US15/638,493 patent/US10030032B2/en active Active
2018
- 2018-07-10 US US16/031,629 patent/US10450324B2/en active Active
- 2018-10-16 JP JP2018194871A patent/JP6634135B2/ja active Active
2019
- 2019-03-26 IL IL265640A patent/IL265640B/en active IP Right Grant
- 2019-12-13 JP JP2019225297A patent/JP6905041B2/ja active Active
2020
- 2020-04-01 IL IL273736A patent/IL273736B/en active IP Right Grant
2021
- 2021-03-04 IL IL281275A patent/IL281275B/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070244187A1 (en) *	2004-06-03	2007-10-18	Eisai Co., Ltd	Intermediates for the Preparation of Halichondrin B

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRIAN AUSTAD ET AL: "Commercial Manufacture of Halaven : Chemoselective Transformations En Route to Structurally Complex Macrocyclic Ketones", SYNLETT, vol. 24, no. 03, 10 January 2013 (2013-01-10), DE, pages 333 - 337, XP055241626, ISSN: 0936-5214, DOI: 10.1055/s-0032-1318026 *
See also references of WO2015085193A1 *

Also Published As

Publication number	Publication date
MX2020004855A (es)	2021-07-08
MX376869B (es)	2025-03-07
BR112016012237A2 (fr)	2017-08-08
WO2015085193A1 (fr)	2015-06-11
US10030032B2 (en)	2018-07-24
US9695188B2 (en)	2017-07-04
US20160176895A1 (en)	2016-06-23
SG10201805024YA (en)	2018-07-30
CN105916861A (zh)	2016-08-31
US20150158881A1 (en)	2015-06-11
IL281275A (en)	2021-04-29
IL245661A0 (en)	2016-06-30
EP3077399A1 (fr)	2016-10-12
US20190010166A1 (en)	2019-01-10
EP3077399B1 (fr)	2019-02-20
MX370611B (es)	2019-12-18
IL273736B (en)	2021-03-25
RU2676486C1 (ru)	2018-12-29
MX2016006891A (es)	2017-06-12
JP2016540752A (ja)	2016-12-28
IL265640A (en)	2019-05-30
JP2019031530A (ja)	2019-02-28
US10450324B2 (en)	2019-10-22
MX2019011926A (es)	2019-11-18
JP2020059739A (ja)	2020-04-16
JP6634135B2 (ja)	2020-01-22
IL273736A (en)	2020-05-31
US20170298078A1 (en)	2017-10-19
IL265640B (en)	2020-04-30
BR112016012237B1 (pt)	2023-02-07
MX384292B (es)	2025-03-14
US9303039B2 (en)	2016-04-05
CA2931788A1 (fr)	2015-06-11
ES2723355T3 (es)	2019-08-26
EP3505520A1 (fr)	2019-07-03
SG11201604545XA (en)	2016-07-28
CA2931788C (fr)	2022-05-24
JP6905041B2 (ja)	2021-07-21
IL281275B (en)	2021-12-01
HUE043088T2 (hu)	2019-08-28
JP6443812B2 (ja)	2018-12-26
CN105916861B (zh)	2018-12-14

Publication	Publication Date	Title
IL281275B (en)	2021-12-01	Methods useful in the synthesis of helichondrin b analogs
IL288468B (en)	2022-10-01	Microcyclization reactions and useful intermediates in the synthesis of helichondrin b analogs
EP3076967A4 (fr)	2017-05-10	Nouveaux procédés
EP2824639A3 (fr)	2015-04-29	Reconstruction du coeur basée sur un modèle à partir d'échantillons éparses
EP3020701A4 (fr)	2017-03-01	Nouveau lipide
GB201421334D0 (en)	2015-01-14	Synthesis of aeizeolite
EP3037145A4 (fr)	2017-05-03	Toupie
EP2965026B8 (fr)	2019-09-11	Production de neige fondue
EP3160970A4 (fr)	2017-12-27	Synthèse d'analogues d'halochondrines et leurs utilisations
EP3014628B8 (fr)	2018-06-06	Procédé de production de germanium-68
EP3065728A4 (fr)	2017-06-07	Nouvelles méthodes
EP3009497A4 (fr)	2017-03-01	Composition nettoyante
EP2994981A4 (fr)	2017-01-11	Vibreur linéaire
EP3055307A4 (fr)	2017-08-02	Berbines substituées et leur synthèse
EP2970319A4 (fr)	2016-11-09	Analogues de 6-acétylmorphine et leurs procédés de synthèse et d'utilisation
ZA201601775B (en)	2017-07-26	Method for the synthesis of irinotecan
PT2799426T (pt)	2016-09-28	Novo processo para a síntese de aminaftona
EP3025677A4 (fr)	2017-03-15	Instrument d'insertion de lentille intraoculaire
EP3068226A4 (fr)	2017-05-17	Nouveaux procédés
IL244411A0 (en)	2016-04-21	A procedure for the synthesis of derivatives of n-benzyl-n-cyclopropyl-1h-pyrazole-4-carboxamide
AU2013903735A0 (en)	2013-10-10	Improvements to Products
GB201322704D0 (en)	2014-02-05	Synthesis
HK1228774A1 (en)	2017-11-10	Novel methods
HK1228772A1 (en)	2017-11-10	Novel methods
AU2013903009A0 (en)	2013-08-22	Safegrip 2

Legal Events

Date	Code	Title	Description
2016-09-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-10-12	17P	Request for examination filed	Effective date: 20160607
2016-10-12	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-10-12	AX	Request for extension of the european patent	Extension state: BA ME
2017-03-15	DAX	Request for extension of the european patent (deleted)
2017-05-10	A4	Supplementary search report drawn up and despatched	Effective date: 20170406
2017-05-10	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 491/22 20060101AFI20170401BHEP
2018-01-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-02-28	17Q	First examination report despatched	Effective date: 20180124
2018-06-25	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2018-06-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-07-02	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-08-01	INTG	Intention to grant announced	Effective date: 20180703
2018-11-07	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2019-01-18	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2019-01-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2019-02-20	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-02-20	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2019-02-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2019-03-14	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014041534 Country of ref document: DE
2019-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1098022 Country of ref document: AT Kind code of ref document: T Effective date: 20190315
2019-03-20	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2019-06-26	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20190220
2019-07-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190620 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190520
2019-08-26	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2723355 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190826
2019-08-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E043088 Country of ref document: HU
2019-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190620 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190521 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190520
2019-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1098022 Country of ref document: AT Kind code of ref document: T Effective date: 20190220
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2019-11-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602014041534 Country of ref document: DE
2019-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2019-12-27	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-12-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2020-01-29	26N	No opposition filed	Effective date: 20191121
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2020-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2020-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191205
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190220
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230511
2025-01-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20241227 Year of fee payment: 11
2025-01-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20241227 Year of fee payment: 11
2025-01-20	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20241226 Year of fee payment: 11
2025-01-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HU Payment date: 20241121 Year of fee payment: 11
2025-01-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20241227 Year of fee payment: 11
2025-01-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20241218 Year of fee payment: 11
2025-04-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20241227 Year of fee payment: 11
2025-04-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250102 Year of fee payment: 11
2025-04-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250108 Year of fee payment: 11